2019 CMHC West - CME Symposia


 ‌

CME General Session· Friday, May 3, 2019 · Phoenix, AZ · 4:15 – 4:45pm

Antithrombotics in Diabetic Patients: Recent Clinical Trial Results

Chaired by: Deepak L. Bhatt, MD

Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD, PAD, and AF compared to patients with these conditions and no concomitant diabetes. As such, current antithrombotic strategies to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. This session will review the results of these trials and their clinical practice implications in order to improve patient outcomes.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Define the association between diabetes and increased thrombotic risk and adverse events in patients with CAD, PAD, or AF
  • Interpret the results of recently concluded clinical trials about the efficacy and safety of novel antithrombotic approaches in patients with diabetes and concomitant CAD, PAD, or AF

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from AstraZeneca.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West, please click here.


 ‌

CME Breakfast Symposium · Saturday, May 4, 2019 · Phoenix, AZ · 7:10 – 8:25am

Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction

Chaired by: JoAnn Lindenfeld, MD

Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life.

To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This live symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Identify HFpEF based on current and emerging diagnostic approaches
  • Develop individualized treatment regimens for HFpEF patients with comorbidities based on current guidelines and evidence
  • Interpret the efficacy and safety of emerging treatment options and therapeutic strategies in HFpEF based on the latest clinical trial evidence
  • List approaches and resources aimed to improve hospital readmission rates for patients with HFpEF

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Abbott and Novartis Pharmaceuticals Corporation.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West, please click here.


 ‌

CME General Session· Saturday, May 4, 2019 · Phoenix, AZ · 10:20 – 11:00am

The Story Continues: Heart Failure and Type 2 Diabetes

Chaired by: Matthew R. Weir, MD

Due to the close association of HF and T2D, it is important that clinicians are aware of the increased morbidity and mortality in this high-risk population. As such, comprehensive strategies to address both HF and T2D are necessary to improve outcomes for these patients. Recent studies have shown that certain antihyperglycemic agents can prevent HF in patients with and without T2D, and several ongoing studies are evaluating the utility of these agents in treating existing HF. This evidence has led to significant guideline changes, and clinicians that treat the complex T2D patient have additional tools in their disposal to improve outcomes. As such, clinicians should be aware of the existing and emerging data, how to interpret these data and more importantly, how to adequately use these agents in clinical practice. This activity will overview the association of HF and T2D, as well as appropriate HF and antihyperglycemic therapy in this setting according to the latest evidence base.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Review the association and the pathophysiology between HF and T2D, and the impact of concomitant HF and T2D on patient outcomes
  • Develop individualized treatment regimens for high-risk patients with HF and T2D based on the latest data about the efficacy and safety of HF and T2D pharmacotherapies and appropriate guideline recommendations

This activity is jointly provided by Annenberg Center for Health Sciences at Eisenhower and CMHC in collaboration with Postgraduate Institute for Medicine. Supported by an educational grant from Boehringer Ingelheim and Lilly USA, LLC.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West, please click here.


 ‌

CME Lunch Symposium · Saturday, May 4, 2019 · Phoenix, AZ · 12:15 – 1:30pm

Advances in Iron Repletion Therapy: Addressing the Burden of Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life

Chaired by: Clyde W. Yancy, MD, MSc, MACP

Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with certain chronic diseases such as chronic kidney disease, and congestive heart failure. Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with heart failure (HF), ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.

In this symposium, experts will provide participants with data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Define the prevalence of iron deficiency (ID) in heart failure (HF) and its impact on patient outcomes and quality of life
  • Identify the symptoms of ID using appropriate markers in HF patients in order to diagnose ID
  • Summarize the evidence from the latest clinical trials of iron repletion in HF patients with ID, as well as the updated ACC/AHA/HFSA guidelines for the management of iron deficiency in patients with HF
  • Develop individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the latest evidence and current guideline recommendations

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from American Regent.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West, please click here.